JAN 02, 2020 9:53 AM PST

FDA Approves Ovarian Cancer Drug to Treat Pancreatic Cancer

WRITTEN BY: Annie Lennon

In 2019, an estimated 46,000 Americans died from pancreatic cancer. Now, the Food and Drug Administration (FDA) has approved Lynparza, an ovarian cancer drug developed by pharmaceutical firm AstraZeneca, to treat patients with advanced stages of the disease. 

Dave Fredrickson, executive vice president of AstraZeneca’s oncology business unit said, “Patients with advanced pancreatic cancer historically have faced poor outcomes due to the aggressive nature of the disease and limited treatment advances over the last few decades.”

Research has suggested that certain variants of the BRCA1 and BRCA2 genes increase one’s risk of developing pancreatic cancer. With normal versions of these genes producing proteins that regulate cells’ ability to both identify and repair damaged DNA, certain variants are unable to do this. These thus lead to the production of malfunctioning proteins, which in turn allow healthy cells to transform into cancer cells, and form tumors.

To combat this process, researchers developed Lynparza, a Poly ADP ribose polymerase (PARP) inhibitor. A protein that repairs a different type of DNA damage than BRCA variants, it disables cells with faulty BRCA from repairing themselves, meaning that, rather than developing into cancer cells, they simply die. 

Clinical trials investigating the drug’s efficacy were positive. Victoria Manax MD., the Chief Medical Officer of Pancreatic Cancer Action Network (PanCAN) said, “The clinical trial results showed a certain subset of metastatic pancreatic cancer patients had a good response to a PARP inhibitor called Lynparza (olaparib) if their tumor had already responded to platinum-containing chemotherapy.” 

She continued, “In the 151 patients treated through this trial, 22.1 percent of patients who received Lynparza had no disease progression two years after starting the treatment, as compared to 9.6 percent of patients who did not receive Lynparza.”

An effective treatment option for those with germline BRCA mutations, the drug should be able to treat between 4 and 7% of pancreatic cancer patients. Julie Fleshman, President and CEO of PanCAN said, “Lynparza is a great example of this big step forward in improving patient outcomes and further confirms the need for all patients to get appropriate testing to determine the best treatment option for them.”



Sources: Pancan 2017, Pancan June 2019Pancan December 2019 and 10tv

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
SEP 27, 2020
Cannabis Sciences
THC Shows Promise in Treating Severe Cases of COVID-19
SEP 27, 2020
THC Shows Promise in Treating Severe Cases of COVID-19
Over the last few months, various headlines have emerged suggesting the potential for cannabinoids, and in particular, c ...
OCT 12, 2020
Drug Discovery & Development
In vitro glycoengineering - Suitability for BioPharma manufacturing
OCT 12, 2020
In vitro glycoengineering - Suitability for BioPharma manufacturing
Introduction The importance of Fc glycosylation of monoclonal antibodies (mAbs) with regard to biological activity is wi ...
NOV 08, 2020
Cell & Molecular Biology
Mouth Spray for Epidermolysis Bullosa in Development
NOV 08, 2020
Mouth Spray for Epidermolysis Bullosa in Development
Epidermolysis Bullosa (EB) is a rare genetic disorder that makes the skin incredibly fragile; it forms blisters and can ...
NOV 08, 2020
Cannabis Sciences
Can Cannabis Treat Epilepsy?
NOV 08, 2020
Can Cannabis Treat Epilepsy?
There has been growing interest in recent years for cannabis to treat central nervous system disorders. And so far, ther ...
NOV 18, 2020
Cancer
Could Targeting the Proteasome be Effective Against Cancer?
NOV 18, 2020
Could Targeting the Proteasome be Effective Against Cancer?
One of the trickiest things about anti-cancer drug design is targeting. Today, most drugs on the market target critical ...
DEC 01, 2020
Immunology
Scar-Free Healing Starts With Mobilizing the Immune System
DEC 01, 2020
Scar-Free Healing Starts With Mobilizing the Immune System
Thanks to a new hydrogel biomaterial developed by researchers at Duke University, we are one step closer to the holy gra ...
Loading Comments...